GLP-1-based therapies, such as GLP-1 receptor agonists, glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors, improve glucose control through various mechanisms including increased insulin secretion, slower gastric emptying, and reduced postprandial glucagon and food intake
Temporary headache or dizziness (reported with limited human use) Safety Considerations None of the significant toxicity indicators were reported in the preclinical tests
These align with the appetite suppression and altered taste perception GLP-1 users experience, directly responding to behavioral shifts in grocery spending and meal habits
However, many people without diabetes can still obtain this prescription drug through less stringent channels and use it for weight loss
Frequent missed doses lead to fluctuating levels that can increase side effects when you do inject and reduce effectiveness overall